Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase Ib/II Clinical Study of LBL-024 Combination Therapy in Patients With Metastatic Colorectal Carcinoma
Sponsor: Nanjing Leads Biolabs Co.,Ltd
Summary
This study is an open-label, multi-center Phase Ib/II clinical trial evaluating the safety and efficacy of LBL-024 in combination with other drugs for the treatment of metastatic colorectal carcinoma (mCRC), aiming to evaluate the safety and efficacy of LBL-024 in combination with other drugs in the treatment of mCRC patients.
Official title: An Open-label, Multicenter Phase Ib/II Study to Evaluate the Safety and Efficacy of LBL-024 Combination Therapy in Patients With Metastatic Colorectal Carcinoma
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
369
Start Date
2026-09-04
Completion Date
2030-09-04
Last Updated
2026-08-28
Healthy Volunteers
No
Conditions
Interventions
LBL-024 for Injection
intravenous infusion.
Bevacizumab injection
intravenous infusion.
Oxaliplatin injection
intravenous infusion.
Capecitabine tablets
Oral.
Fruquintinib Capsules
Oral.
Locations (1)
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China